|Dr. Henry H. Ji Ph.D.||Chairman, Pres & CEO||1.69M||34.1k||1964|
|Ms. Elizabeth Adkins Czerepak M.B.A.||Exec. VP, CFO & Chief Bus. Officer||8.12k||N/A||1956|
|Mr. Brian Cooley||Sr. VP of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Mr. William J. Farley B.Sc.||VP of Sales & Bus. Devel.||N/A||N/A||1956|
|Dr. Michael A. Royal||SVP & Chief Medical Officer||N/A||N/A||1954|
|Dr. Alexis Nahama D.V.M.||Sr. VP of Neurotherapeutics BU||N/A||N/A||N/A|
|Dr. Mark R. Brunswick||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
|Dr. Shawn Sahebi Ph.D.||Sr. VP of Commercial Operations||N/A||N/A||N/A|
|Dr. Robert D. Allen Ph.D.||Sr. VP of R&D||N/A||N/A||N/A|
|Dr. Xiao Xu M.D.||Pres of ACEA||N/A||N/A||N/A|
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
Sorrento Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2022 is 10. The pillar scores are Audit: 6; Board: 9; Shareholder rights: 6; Compensation: 10.